# Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Recifercept in Healthy Chinese Participants

> **NCT05061277** · PHASE1 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Recifercept

## Key facts

- **NCT ID:** NCT05061277
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-10-25
- **Primary completion:** 2023-12-12
- **Final completion:** 2024-06-16
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Pfizer has decided to cancel study C4181006 due to strategic considerations. This decision is not due to any specific reasons or requests from any regulatory authorities. No participants have been enrolled in this study.
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05061277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05061277, "Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Recifercept in Healthy Chinese Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05061277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*